Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 38Myelodysplastic Syndromes 9Leukemia 6Leukemia, Monocytic, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Burkitt Lymphoma 2Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphoid 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrence × CPX-351 × Clear all
NCT03826992 2026-02-18

Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

Children's Hospital Medical Center, Cincinnati

Phase 1 Recruiting
21 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡